Daniel R.
70 lbs lost on tirzepatide. Then 6 months of nothing. The visceral fat that GLP-1 alone couldn't touch finally met its match.
After plateauing at 198 lbs for 6 months, a Three-System peptide protocol reduced visceral adipose tissue by 45% — from 168 cm² to 92 cm² — and dropped his waist from 38 to 33 inches. Without escalating his GLP-1.
The Plateau No One Told Him About
Daniel is a 42-year-old commercial real estate broker — 60+ hour work weeks built around client meetings, business dinners, and frequent travel. Married, no kids, with a disciplined morning routine and a training schedule he'd maintained through his entire weight loss arc. Over 14 months on tirzepatide, he had lost 70 lbs: from 268 down to 198. That transformation was real, hard-won, and something he was genuinely proud of.
Then he stopped moving. For 6 months, his weight sat between 198 and 202 lbs regardless of what he did. The subcutaneous fat had responded well — but his lower abdomen told a different story. The visceral fat pattern that had driven his original health risks remained largely intact, giving him what he described as a "skinny-fat" abdomen profile even at his new weight. He didn't want to escalate tirzepatide to 12.5mg — he had already tried it, found the side effects intolerable, and walked back the dose. He needed a different approach.
He came to FLOA having researched AOD-9604 and Tesamorelin online but skeptical of the evidence — particularly for AOD-9604. He wanted clinical supervision, DEXA verification with visceral-specific measurement, and a protocol built around the system that had actually stalled, not just higher doses of what he was already taking.
What 6 Months of Plateau Looked Like
- 6-month GLP-1 plateau at 198–202 lbs despite maintained tirzepatide 10mg and active training
- Visceral adipose tissue (VAT) at 168 cm² — well above the optimal threshold of 100 cm², DEXA-confirmed
- Waist stuck at 38 inches — down from 44 inches but unresponsive to further intervention
- Subcutaneous fat responsive to GLP-1; visceral fat essentially non-responsive
- Free testosterone declined from 612 to 478 ng/dL total T — suspected suppression from GLP-1 and caloric restriction during weight loss arc
- Free T low-normal at 9.8 pg/mL — contributing to declining lifting capacity and sarcopenic lean-to-fat shift
- IGF-1 at 142 ng/mL — low-normal, limiting fat mobilization and lean mass preservation
- Lifting capacity declining during plateau — suspected lean mass erosion despite stable scale weight
- Tirzepatide 12.5mg escalation already attempted and abandoned — side effects intolerable
- Aggressive cardio block during plateau: lost 4 lbs of muscle with no fat change
- hs-CRP 2.1 mg/L — improved from pre-tirzepatide 4.8 but plateaued alongside weight
The Three-System Framework — Each Peptide a Different Target
Visceral-specific DEXA assessment with VAT measurement in cm² — not just total body fat percentage. Full hormone and metabolic panel: free T, SHBG, IGF-1, fasting insulin, HOMA-IR. GLP-1 protocol review and de-escalation strategy. Three-System Framework assessment mapping appetite control, fat mobilization, and metabolic enhancement as distinct intervention targets. Body composition modeling for specific VAT reduction goals.
GLP-1 reduced from 10mg to 5mg over a 4-week step-down to avoid rebound hunger, then to 2.5mg microdose maintenance post-protocol. The goal was to maintain appetite control at the lowest effective dose while removing the high-dose GLP-1 contribution to testosterone suppression and lean mass erosion. Daniel's plateau was not an appetite problem — reducing the GLP-1 while adding targeted fat-mobilization peptides addressed the actual mechanism.
AOD-9604 is a modified fragment of the hGH molecule (amino acids 176–191) that retains the lipolytic properties of growth hormone without affecting IGF-1 or insulin-like activity. At 300 mcg subcutaneously on a 5-on/2-off cycle, it directly stimulates fat cell breakdown and inhibits new fat storage — the supply-side fat mobilization mechanism that GLP-1's demand-side appetite suppression cannot reach. 8-week cycle with 4-week off period.
Tesamorelin is an FDA-approved GHRH analogue with a specific clinical indication for visceral adipose tissue reduction. At 1mg subcutaneously, dosed in the evening to align with the natural GH pulse window, it stimulates endogenous GH release with preferential effect on visceral fat depots — the exact tissue type that had proven resistant to tirzepatide alone. 12-week intensive phase; reassessment for maintenance cycling. The visceral-specific mechanism is what separates Tesamorelin from general fat-loss approaches.
Resistance training increased from 2x to 4x/week — reversing the cardio-heavy approach that had cost him lean mass during the plateau. Protein increased to 198g/day (1g/lb body weight) to support lean mass recovery alongside fat loss. Coaching team supported nutrition execution around travel and client entertainment commitments. Cardio volume reduced to protect against further lean mass erosion.
Phase by Phase
GLP-1 Step-Down Tolerated — No Rebound Hunger
Tirzepatide reduction from 10mg to 5mg tolerated without rebound hunger — the first confirmation that his plateau was not an appetite regulation failure. Mild Tesamorelin injection-site soreness noted, expected and manageable. Protocol fully initiated across all three systems.
→ GLP-1 step-down tolerated; all three systems active
Visceral Softening — Strength Returning — Testosterone Rising
Subjective abdominal "softening" reported — the first perceptible change in the visceral fat pattern. Resistance training capacity returning as free testosterone began to climb from 478 toward 542 ng/dL. Scale weight unchanged — expected, as the protocol was producing a composition shift, not a simple deficit-driven weight loss.
→ Visceral softening; free T rising; strength returning; weight stable (by design)
Waist Down 1.5 Inches — Lifting Numbers Improving
Visible waist reduction: 38 inches to 36.5 inches — the first measurable external change after 6 months of nothing. Scale weight down 4 lbs, but the composition shift was the story: fat was dropping while lean mass held. Lifting capacity measurably improving. Plateau definitively breaking.
→ Waist 36.5″; down 4 lbs composition-driven; lifting improving
DEXA Confirms: VAT Down 50 cm² — Primary Target Hit
Month 3 DEXA: VAT from 168 cm² to 118 cm² — a 50 cm² reduction in visceral adipose tissue, the primary clinical target. Lean mass up 2.8 lbs. Total fat down 8.4 lbs. IGF-1 from 142 to 195 ng/mL. The structural evidence matched the subjective and external changes — visceral fat was responding to Tesamorelin and AOD-9604 after 6 months of complete resistance to GLP-1 escalation.
→ VAT 118 cm²; lean +2.8 lbs; fat -8.4 lbs; IGF-1 195
VAT into Optimal Range — Protocol Complete
Tesamorelin continued at lower maintenance dose. AOD-9604 cycled off. Tirzepatide reduced to 2.5mg microdose weekly — a fraction of his prior 10mg dose. Final VAT measurement: 92 cm² — inside the optimal threshold of 100 cm² for the first time. Waist at 33 inches. Total outcome: 18 lbs of fat lost, 4.2 lbs of lean mass gained, plateau definitively broken.
→ VAT 92 cm² (optimal); waist 33″; 18 lbs fat lost; lean mass gained
"GLP-1 drugs reduce appetite and improve insulin sensitivity — they do not selectively mobilize visceral adipose tissue. Visceral fat is metabolically distinct from subcutaneous fat: it has higher density of glucocorticoid receptors, different adrenergic sensitivity, and requires a different pharmacological signal to release. Daniel's subcutaneous fat had responded to tirzepatide. His visceral fat was waiting for Tesamorelin — a GHRH analogue with an FDA indication specifically for this tissue type."
What Changed at 6 Months
Visceral Fat (DEXA)
VAT from 168 cm² → 92 cm² — a 45% reduction and entry into the optimal threshold for the first time. The primary outcome of the entire protocol, achieved without dose escalation.
Waist Circumference
38 inches → 33 inches — 5 inches of waist reduction in 6 months, after 6 months of zero movement on tirzepatide 10mg alone. The "skinny-fat" abdomen profile resolved.
Body Composition
18 lbs total fat lost. Lean mass gained +4.2 lbs — reversing the sarcopenic trend that had developed during the plateau. DEXA-confirmed at baseline, month 3, and month 6.
Testosterone & IGF-1
Free T from 9.8 → 16.4 pg/mL as GLP-1 dose reduced and lean mass recovered. IGF-1 from 142 → 198 ng/mL. Both markers contributing to restored lifting capacity and recovery.
GLP-1 Dose Reduction
Tirzepatide from 10mg → 2.5mg biweekly — a 75%+ dose reduction. Lower side effect burden, lower cost, lower long-term dependency. Appetite control maintained at minimum effective dose.
Metabolic Markers
hs-CRP from 2.1 → 0.7 mg/L. HOMA-IR from 1.8 → 1.2. Fasting insulin normalized. The metabolic improvements that stalled alongside the weight plateau resumed once visceral fat mobilization began.
| Category | What Changed |
|---|---|
| Visceral Fat | 168 → 92 cm² on DEXA — 6 months of GLP-1 resistance broken in one targeted protocol |
| Waist | 38″ → 33″ — 5 inches in 6 months after 6 months of complete stagnation |
| Plateau | 6-month GLP-1 plateau broken without dose escalation — the exact goal coming in |
| Lean Mass | +4.2 lbs — sarcopenic trend during plateau reversed; lifting capacity restored |
| Free Testosterone | 9.8 → 16.4 pg/mL — suppression from high-dose GLP-1 reversed as dose stepped down |
| GLP-1 Dose | 10mg → 2.5mg biweekly — lower side effects, lower cost, sustainable long-term |
| Lifting Capacity | Declining during plateau → restored to pre-plateau levels by month 6 |
| Abdomen Profile | "Skinny-fat" visceral pattern resolved — body composition matches the 70-lb transformation |
| Inflammation | hs-CRP 2.1 → 0.7 — stalled inflammatory improvement resumed with VAT reduction |
"I lost 70 lbs and I'm proud of that. But for six months I stared at the same number on the scale and the same belly in the mirror. I tried escalating the tirzepatide — the side effects were brutal. I tried more cardio — I just lost muscle. FLOA actually looked at what type of fat was stuck, explained why GLP-1 alone couldn't reach it, and built a protocol around that specific problem. My waist went from 38 to 33 inches. My DEXA shows I gained muscle while losing fat. And I'm now on a fraction of the tirzepatide dose I was on before. That's the outcome I came in for."
Clinical Takeaways
Daniel's case illustrates a fundamental limitation of GLP-1 therapy that is rarely communicated to patients: these medications reduce appetite and improve insulin sensitivity, but they do not selectively mobilize visceral adipose tissue. Visceral fat is metabolically distinct — it has higher density of glucocorticoid receptors, different adrenergic sensitivity, and a preferential response to growth hormone signaling rather than insulin-mediated pathways. When a patient plateaus on GLP-1 with persistent visceral fat, the answer is not a higher GLP-1 dose. It is a different mechanism.
Tesamorelin's clinical utility here is not hypothetical. It carries an FDA indication specifically for visceral fat reduction — and its mechanism, stimulating endogenous GH release via the GHRH pathway, directly targets the hormonal signal that drives visceral adipose mobilization. AOD-9604 complemented this by activating lipolysis at the fat cell level without affecting IGF-1 or insulin dynamics. Together they addressed the fat type that GLP-1 had left untouched, through pathways that GLP-1 does not engage.
The GLP-1 step-down was also clinically meaningful. High-dose tirzepatide over a 14-month arc had contributed to testosterone suppression and lean mass erosion — a common and underappreciated consequence of prolonged aggressive GLP-1 use. Reducing to 2.5mg while replacing the fat-mobilization function with targeted peptides allowed Daniel's testosterone to recover, his lean mass to rebuild, and his lifting capacity to return — outcomes that dose escalation would have worked directly against.
If Your GLP-1 Has Stopped Working — the Dose Isn't the Answer
Visceral fat doesn't respond to appetite suppression alone. If you've plateaued on GLP-1 with a persistent abdominal fat pattern, a targeted protocol built around the specific tissue type — and verified by DEXA — may be the layer that was always missing.
Individual results vary. This case study is for educational purposes only. © Dr. Jones DC — FLOA Protocol.